Cystic Fibrosis Foundation - Click here for homepage
Stay Informed  |  Volunteer  |  Clinical Trials

In This Section

Quick Links

Find a Chapter

Get Assistance

Get Assistance - Cox Boys
We are here to help people with CF get the insurance coverage they need. Hear how the Foundation helped the Cox family.

Join us on Facebook!  Facebook 
Follow us on Twitter!   Twitter
Follow us on Instagram!  Instagram 
Add us to your circle in Google+!

Google+ 

Subscribe to our channel on YouTube!  YouTube  


 

 

Bookmark and Share   Print  

New Funding Opportunities

The Cystic Fibrosis Foundation and Cystic Fibrosis Foundation Therapeutics announce these new funding opportunities for 2015.


Screening Improvement Program (SIP) for Optimizing the Diagnosis of Infants 

Early pre-symptomatic diagnosis through newborn screening (NBS) provides an opportunity to help control the disease through preventive medicine strategies and thereby enhance quality of life. After demonstration of benefits and endorsement — by both the Centers for Disease Control and Prevention and the Cystic Fibrosis Foundation (CFF)  — the implementation of NBS for CF from 2006 to 2009 across the United States has provided many new opportunities for enhanced care, teaching, and research, but also occurred with such relative rapidity that a need for quality improvement and assurance has become apparent.

To this end, the CF Foundation has developed a Screening Improvement Program for Optimizing the Diagnosis of Infants. The Foundation invites quality improvement proposals from leaders of U.S. programs for projects designed to expedite the early diagnosis of CF through NBS.

The sponsoring institution should have a CF Foundation-accredited care center or affiliate program. The CF care center director or affiliate director must provide a letter affirming that the applicant will be integrated into the CF care center.

Each application should also engage the director of the regional NBS laboratory. All applicants must be either a U.S citizen or have a permanent resident visa. Proof of citizenship status is required at time of application.

Successful applicants will receive funding of up to $30,000 direct costs per year (plus 8% indirect costs) for one year and may be eligible for up two years. 

Please review the Policies and Guidelines for details and submission information.


Modulating CFTR Gene Expression for Therapeutic Advantage 

The discovery of drugs that increase CFTR activity and/or residence in the plasma membrane to levels which result in clinical benefit is a milestone in drug development for human disease. This precedent suggests that such drugs may be even more effective if they have additional substrate on which to act. 

Cystic Fibrosis Foundation Therapeutics (CFFT) is soliciting proposals that will investigate the regulation of CFTR mRNA levels and methods to increase those levels. 

Additionally, this RFA seeks projects that will increase the translational efficiency and stability of CFTR mRNA as a potential mechanism for increasing CFTR protein expression. 
                                                                                                                                             
 CFFT is interested in proposals that will improve our understanding of:

  • The CFTR promoter
  • Splice modulation
  • Transcriptional activation
  • Other gene regulation mechanisms (i.e., microRNA, lncRNA, etc.)

Proposals will be accepted in three categories:

Please review the Policies and Guidelines for details and submission information.

Updated: 3/5/2015

back to top

The Cystic Fibrosis Foundation is an accredited charity of the Better Business Bureau.